Neurogene Inc. — Director's Dealing 2021

Feb 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Neoleukin Therapeutics, Inc. (NLTX)
CIK: 0001404644
Period of Report: 2021-01-30

Reporting Person: Walkey Carl (Senior Vice President)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-30	Stock Option (Right to Buy)	$12.60	A	45000	Acquired	2031-01-30	Common Stock (45000)	Direct

Footnotes

F1: The option vests as to 1/4 of the total shares on January 30, 2022, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.